Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes by Rundgren, Ida Marie et al.
molecules
Article
Immunomodulatory Drugs Alter the Metabolism and
the Extracellular Release of Soluble Mediators by
Normal Monocytes
Ida Marie Rundgren 1,2, Anita Ryningen 1, Tor Henrik Anderson Tvedt 3, Øystein Bruserud 2,3,*
and Elisabeth Ersvær 1
1 Department of Biomedical Laboratory Scientist Education and Chemical Engineering, Faculty of
Engineering and Natural Sciences, Western Norway University of Applied Sciences, 5020 Bergen, Norway;
imru@hvl.no (I.M.R.); anita.ryningen@hvl.no (A.R.); elisabeth.ersver@hvl.no (E.E.)
2 Department of Clinical Science, University of Bergen, 5020 Bergen, Norway
3 Section for Hematology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway;
tor.henrik.anderson.tvedt@helse-bergen.no
* Correspondence: oystein.bruserud@helse-bergen.no
Academic Editor: Jóhannes Reynisson FRSC
Received: 20 December 2019; Accepted: 13 January 2020; Published: 16 January 2020


Abstract: Immunomodulatory drugs (IMiDs) are used in the treatment of hematological malignancies,
especially multiple myeloma. IMiDs have direct anticancer effects but also indirect effects via
cancer-supporting stromal cells. Monocytes are a stromal cell subset whose metabolism is modulated
by the microenvironment, and they communicate with neighboring cells through extracellular release
of soluble mediators. Toll-like receptor 4 (TLR4) is then a common regulator of monocyte metabolism
and mediator release. Our aim was to investigate IMiD effects on these two monocyte functions.
We compared effects of thalidomide, lenalidomide, and pomalidomide on in vitro cultured normal
monocytes. Cells were cultured in medium alone or activated by lipopolysaccharide (LPS), a TLR4
agonist. Metabolism was analyzed by the Seahorse XF 96 cell analyzer. Mediator release was
measured as culture supernatant levels. TLR4 was a regulator of both monocyte metabolism and
mediator release. All three IMiDs altered monocyte metabolism especially when cells were cultured
with LPS; this effect was strongest for lenalidomide that increased glycolysis. Monocytes showed a
broad soluble mediator release profile. IMiDs decreased TLR4-induced mediator release; this effect
was stronger for pomalidomide than for lenalidomide and especially thalidomide. To conclude,
IMiDs can alter the metabolism and cell–cell communication of normal monocytes, and despite their
common molecular target these effects differ among various IMiDs.
Keywords: monocytes; immunomodulatory drugs; cell metabolism; cytokines
1. Introduction
The immunomodulatory drugs (IMiDs) are widely used in the treatment of multiple myeloma and
are also considered for the treatment of other hematological malignancies [1]. Cereblon is a common
molecular target for IMiDs, and the drugs can have direct anticancer effects on malignant cells or
indirect effects mediated via cancer-supporting nonmalignant cells (e.g., antiangiogenic effects) [2].
Monocytes are important both for immunoregulation and for regulation of normal and malignant
hematopoiesis [3,4], and IMiD effects on monocytes may therefore be important both for their efficiency
and toxicity in anticancer treatment.
Monocytes undergo morphological, phenotypic, and functional changes in response to their
metabolic microenvironment [5]. Most circulating monocytes have a classical phenotype and their
metabolism can be altered by ligation of Toll-like receptor 4 (TLR4), e.g., by lipopolysaccharide (LPS) or
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certain metabolites (e.g., oleic acid, palmitic acid), and the downstream NFκB activation following TLR4
ligation [6]. However, very high levels of TLR4 ligands may instead induce tolerance [7]. Cholesterol,
triglyceride-rich lipoproteins, low density lipoproteins (LDL), very low density lipoproteins (VLDL)
and high density lipoprotein (HDL) can also modulate the monocyte phenotype through non-TLR4
mechanisms and thereby alter the balance between pro- and anti-inflammatory effects [5–8]. Finally,
even dietary intake seems to influence the phenotypic characteristics of monocytes, including the
balance between pro- and anti-inflammatory effects [8]. Thus, monocyte functions are modulated by
the monocyte’s metabolic status/environment.
TLR4 receptors can be activated not only by microbial products but also by endogenous ligands
as described above [9,10]. TLR4 ligation can stimulate monocyte release of several cytokines [11,12]
and at the same time also activate a metabolic switch towards glycolysis leading to production of
metabolites that are important for the pentose–phosphate pathway, fatty acid synthesis, and amino
acid metabolism [8]. This relative block in the citric acid cycle will increase the availability of citric acid
and succinate with further modulation of phospholipid and cholesterol synthesis [13,14]. Thus, the
balance between glycolysis and oxidative phosphorylation is not only modulated by TLR4 ligands
but also by the metabolomic profile of the extracellular microenvironment [15], e.g., glutamine that
both feeds into the tricarboxylic acid cycle and also acts as a regulator of TLR4 responses [13,16].
These examples further illustrate the complex overlap/crosstalk between TLR4 signaling, metabolic
regulation, and extracellular mediator release.
Monocytes can influence the development of various malignancies through direct and indirect
effects [17], possibly also multiple myeloma. First, the balance between various leukocyte subsets in
peripheral blood seems to have a prognostic impact, and high neutrophil- or monocyte-to-lymphocyte
ratios at the time of diagnosis are associated with unfavorable clinicobiological features [18]. Secondly,
monocytes can modulate the cell surface molecular profile of the myeloma cells [19]. Third, activated
monocytes release cytokines that directly stimulate myeloma cell proliferation or indirectly facilitate
disease progression, e.g., through increased angiogenesis [20,21]. Finally, monocyte-derived dendritic
cells can present myeloma-associated antigens [22], whereas monocyte-derived myeloid-derived
suppressor cells have immunosuppressive effects [23]. Thus, monocytes may influence myeloma
development/progression and susceptibility to chemotherapy, but the final effects are difficult to predict.
The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide are
widely used in myeloma treatment [24] and can inhibit TLR4/LPS-induced secretion of inflammatory
cytokines [25]. Cereblon is a common molecular target for these drugs, but their cereblon binding
as well as their clinical effects in myeloma treatment differ [2]. As described above there may be a
crosstalk between TLR4 signaling, metabolic modulation, and capacity of cytokine release in normal
monocytes. In this context we have compared the effects of these IMiDs on monocyte metabolism and
release of soluble mediators by normal monocytes.
As described above monocytes seem to support disease development in multiple myeloma [17],
but because monocytes are a part of the bone marrow stem cell niches they may also influence
the development and chemosensitivity of other hematological malignancies, e.g., through their
release of leukemia-supporting cytokines [4]. IMiDs are therefore considered for the treatment of
other hematological malignancies [2]. The aim of the present study was to use standardized in vitro
models to investigate how various IMiDs influence important phenotypic characteristics of normal
monocytes and whether these effects differ among various IMiDs that have cereblon as a common
molecular target [26]. Thus, monocytes are important in physiological immunoregulation as well as
in carcinogenesis, and our goal was to investigate IMiD effects on metabolic regulation and cytokine
release; two functional characteristics that seem to be important are the roles of normal monocytes in
both immunoregulation and carcinogenesis [8,17].
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2. Results
2.1. TLR4/LPS Activation Alters the Balance between Glycolysis and Oxidative Phosphorylation in the
Direction of Glycolysis
Monocytes derived from 10 healthy blood donors (4 males and 6 females; median age 33 years
with range 25–71 years) were incubated for four hours in medium with and without LPS; the cells
were thereafter incubated for one hour without CO2 before cell metabolism was analyzed. We first
investigated the basal mitochondrial metabolism (see Supplementary Figure S1 upper part) of the
monocytes; the balance between oxidative phosphorylation (oxygen consumption rate, OCR) and
glycolysis (i.e., extracellular acidification rate, ECAR) is presented as the OCR:ECAR ratio. The results
from a representative experiment are presented in Supplementary Figure S1 (lower part).
Preincubation for four hours with LPS 1 ng/mL decreased the OCR:ECAR ratio significantly,
compared with the medium control (Figures 1a and 2A). A similar effect on the OCR:ECAR ratio was also
seen when analyzing the maximal respiration period where LPS also decreased this ratio significantly
(Figures 1b and 2D). Thus, LPS altered the balance between glycolysis and oxidative phosphorylation
in the direction of glycolysis, but LPS did not alter the coupling efficiency (i.e., the efficiency of
mitochondrial ATP production) or spare respiratory capacity (i.e., showing how much of the respiratory
capacity was being used) (Figure 1c).
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thalidomide, lenalidomide or pomalidomide. The figures show the results for (a) the OCR:ECAR ratio 
during the initial period of basal incubation; (b) the period of maximal respiration after addition of 
FCCP (Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone; an uncoupling agent); and (c) the 
calculated spare respiratory capacity. The figure summarizes the results for 10 independent 
experiments testing monocytes from 10 healthy blood donors. The results are presented as median, 
box (i.e., the 25–75 percentiles) and whiskers (the 5–95 percentiles). The Wilcoxon test for paired 
samples was used for the statistical comparisons, and p-values < 0.05 were regarded as statistically 
significant. The significant comparisons are indicated in the figure (* p < 0.05, ** p < 0.01). 
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We then investigated the effects of the three IMiDs on the OCR:ECAR ratio in the presence of 
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Figure 1. Analysi of monocyte metabolism using the XF Mito Stres Test as ay and the Seahorse 96
cell analyzer; a summary of the overall results. Normal mon cytes wer cultured in mediu al or
in the presence of LPS (lipopolysaccharide) 1 ng/mL, or IMiDs (immuno odulatory drugs) 5 µg/mL for
four hours before the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were
determined. Each of the figures presents the OCR:ECAR ratio (diagrams (a,b)) or the spare respiratory
capacity (diagram (c)) for cultures prepared in (from the bottom to the top of each diagram) (i) medium
alone (ctr), (ii) LPS control, (iii) each of the IMiDs—thalidomide, lenalidomide, or pomalidomide—in
medium alone without LPS; and (iv) LPS in combination with either thalidomide, lenalidomide or
pomalidomide. The figures show the results for (a) the OCR:ECAR ratio during the initial period of
basal incubation; (b) the period of maximal respiration after addition of FCCP (Carbonyl cyanide-4
(trifluoromethoxy) phenylhydrazone; an uncoupling agent); and (c) the calculated spare respiratory
capacity. The figure summarizes the results for 10 independent experiments testing monocytes from 10
healthy blood donors. The results are presented as median, box (i.e., the 25–75 percentiles) and whiskers
(the 5–95 percentiles). The Wilcoxon test for paired samples was used for the statistical comparisons,
and p-values < 0.05 were regarded as statistically significant. The significant comparisons are indicated
in the figure (* p < 0.05, ** p < 0.01).
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Figure 2. The effects of IMiDs on the metabolism of normal monocytes; a presentation of statistically
significant effects of LPS and IMiDs on the OCR:ECAR ratio, (A–C) is OCR:ECAR ratio at basal levels
and (D–H) at maximal respiration. Nor al onocytes derived fro 10 different healthy individuals
were cultured with and without LPS 1 ng/mL and/or with and without IMiDs 5 µg/mL in the presence of
LPS. Metabolism was analyzed using the XF Mito Stress Test assay and the Seahorse XF 96 cell analyzer.
The figure presents the results for all statistically significant comparisons. The culture conditions that
were compared in each of the statistical analyses/diagrams are indicated on the x-axis, the OCR:ECAR
ratio is indicated on the y-axis and the corresponding p-values from the statistical analyses (Wilcoxon
test for paired samples) are indicated at the top of each diagram. We present the results from analysis
of basal (A–C) and maximal respiration (D–H). Each diagram compares the results for (i) cultures
prepared with medium alone versus LPS (A,D); (ii) cultures prepared with LPS without and with an
IMiD (B,F,G), and (iii) cultures prepared with two different IMiDs but otherwise with similar culture
conditions (E,H).
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2.2. IMiDs Differ in Their Effects on the Balance between Glycolysis and Oxidative Phosphorylation; Especially
Lenalidomide Increases Oxidative Phosphorylation
We first investigated whether thalidomide, lenalidomide, and pomalidomide altered monocyte
metabolism when cells from 10 healthy individuals were cultured in medium alone without TLR4/LPS
stimulation. The OCR:ECAR ratio was not significantly altered by any of the IMiDs when analyzing
the initial basal metabolism or the maximal respiration (Figure 1a,b).
We then investigated the effects of the three IMiDs on the OCR:ECAR ratio in the presence of
LPS/TLR4 ligation, i.e., an intervention that alters the metabolic balance in the direction of glycolysis
(see above). Lenalidomide caused a significant increase in this ratio when testing the cells under basal
conditions (Supplementary Figure S1 lower part, Figures 1a and 2B), but for 8 out of the 10 tested
individuals the ratio was still lower for the lenalidomide cultures than for the medium controls. The
lenalidomide levels were also significantly different from the thalidomide values (Figure 2C) but did
not differ significantly from pomalidomide (data not shown). Thus, lenalidomide was the only IMiD
that significantly altered monocyte metabolism and decreased the relative importance of glycolysis
(i.e., increased the OCR:ECAR ratio) in the presence of TLR4/LPS activation.
We also investigated the OCR:ECAR ratio during maximal respiration (see Figures 1–3). The ratio
was significantly higher for lenalidomide than for pomalidomide when testing normal monocytes
incubated in medium alone without LPS (Figure 2E). In the presence of LPS the IMiDs had different
effects on the OCR:ECAR ratio; lenalidomide caused a highly significant increase (Figure 2F) whereas
pomalidomide caused an increase of borderline significance (Figure 2G). The ratio was significantly
higher for lenalidomide than for thalidomide (Figure 2H) in the presence of LPS.
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2.3. IMiDs Have Different Effects on the Spare Respiratory Capacity of Normal Monocytes
We first investigated the effects of the three IMiDs on the spare respiratory capacity in the
absence of TLR4/LPS stimulation; none of the drugs then had any significant effect (Figure 1). We
also investigated the effects of the three IMiDs on the spare respiratory capacity in the presence of
TLR4/LPS stimulation (Figures 1 and 3). All three IMiDs altered this capacity significantly compared
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with the LPS control cultures (Figure 3a–c). Lenalidomide then caused a highly significant increase
(Figure 3b, p = 0.007), and this lenalidomide effect was significantly stronger than the increase caused
by thalidomide (Figure 3d) and the decrease caused by pomalidomide (Figure 3e). Thus, the differences
among IMiDs with regard to modulation of monocyte metabolism are not only reflected in OCR:ECAR
ratio but also in the spare respiratory capacity.
2.4. Healthy Individuals Differ in Their Spontaneous and TLR4/LPS-Induced Mediator Release
We investigated the spontaneous release of 14 soluble mediators for normal monocytes derived
from 15 healthy individuals (7 males and 8 females, median age 48 years with range 23–71 years).
Monocytes showed a spontaneous mediator release, but these levels were relatively low and varied
between patients (Supplementary Table S1, Figure 4).Molecules 2020, 25, x FOR PEER REVIEW 7 of 18 
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results. Normal monocytes were cultured in medium alone or in the presence of LPS 1 ng/mL, or IMiD
5 µg/mL for 24 h before supernatants were harvested and the supernatant levels of the 14 soluble
mediators determined. Each of the diagrams/figures present the level for cultures prepared in (from
the bottom to the top of the figure) (i) medium alone (ctr), (ii) LPS + DMSO alone, (iii) each of
the IMiDs—thalidomide, lenalidomide or pomalidomide—in combination with either thalidomide,
lenalidomide, or pomalidomide. The diagrams show the results for each individual soluble mediator.
The results are presented as the median, box (i.e., 25–75 percentiles), and whiskers (5–95 percentiles).
The Wilcoxon test for paired samples was used for all statistical comparisons, and p-values < 0.05 were
regarded as statistically significant. All statistically significant comparisons are indicated in the figure
(* 0.01 < p < 0.05, ** p < 0.01, *** p < 0.001).
For seven of these individuals we also investigated the release in cultures prepared in medium
with LPS 1 ng/mL. As expected we observed a LPS-induced increased in soluble mediator release,
and the levels did not differ significantly when we compared cultures with LPS alone and cultures
with LPS + DMSO (i.e., the control cultures for the IMiD experiments) (data not shown). Thus, the
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TLR4/LPS-induced mediator response was maintained in the presence of the DMSO concentration used
in our IMiD experiments, and the LPS response is reflected in the difference between the spontaneous
levels presented in Supplementary Table S1 and the levels in the DMSO containing control cultures
presented in Table 1 (see also the overview in Supplementary Figure S2). Finally, LPS significantly
increased the levels for all soluble mediators except for CCL1 and CXCL10, and there were no significant
correlations between the spontaneous release for cultures prepared in medium alone and the LPS
cultures, except for IL10 (r-value 0.821, p-value 0.001) and MMP9 (r-value 0.621, p-value 0.018).
We did a hierarchical clustering analysis of the TLR4/LPS-induced mediator release for the 15
healthy individuals (Supplementary Figure S3). These results are presented as the relative responses,
i.e., the levels in LPS containing cultures versus the levels in control cultures prepared in medium
alone. The TLR4/LPS responsiveness differed among individuals, and a strong response was seen
especially for the lower six individuals (2, 10, 6, 7, 3, 1) that clustered together. We performed similar
analyses for thalidomide/lenalidomide/pomalidomide containing cultures, and these analyses showed
that similar variations among individuals in TLR4/LPS responsiveness (i.e., variations in absolute
mediator levels persisted also in the presence of IMiDs) (data not shown).
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Table 1. The effects of thalidomide, lenalidomide, and pomalidomide on TLR (Toll like receptor) 4 -induced release of soluble mediators by normal monocytes derived
from healthy individuals. The data are presented as the median and range of the levels detected in culture supernatants. Fifteen healthy individuals were examined.






















CCL1 63.8 (0.6–1229) 40.7 (1.1–994) n.s. 22.2 (0.4–406) n.s. 10.4 (0.6–191) n.s
CCL2 11,479 (30.3–26,405) 6751 (32.4–24,724) 0.036 1816 (34.5–10,349 0.003 461 (40.8–6173) 0.001





CCL4 43,275 (409–86,040) 48,452 (359–90,664) n.s. 30,375 (437–66,560) 0.031 13,308 (394–31,896) 0.003
CCL7 1274 (39,7–3571) 1088 (39.8–3473) n.s. 524 (50.7–1724) 0.011 410 (9.1–485) 0.003
CXCL1 46,239 (161–70,248) 47,546 (177–76,381) n.s. 56.508 (214–83,477) n.s. 43,350 (218–71,720) n.s
CXCL10 8.3 (<0.1–86.3) 9.3 (<0.1–69.7) n.s. 8.2 (<0.1–49.1) n.s. 7.5 (<0.1–102) 0.019
Interleukins
IL1β 13,578 (34,9–19,091) 20,310(37.4–66,422) n.s. 6363 (33.4–15,877) 0.02 580 (31.8–2442) 0.001
IL1RA 97,396 (130–66,232) 29,043(102–158,380) 23,839 (137–91,545) n.s. 19,870 (168–93,618) n.s
IL6 117,615 (2928–104.657) 117,722(1324–60,904)
77,344
(865–125,094) 0.0125 32,080 (615–61,886) 0.0007





IL10 931 (<2.1–2500) 1255 (<2.1–1743) 0.038 1082 (<2.1–1573) n.s. 1092 (<2.1–1573) n.s
Other mediators
MMP9 3943 (50–10,680) 2862 (8.2–8639) n.s. 2895 (18.5–9801) n.s. 4856 (28.3–11,681) n.s
TNFα 17,983 (46–21,758) 7366 (33–60,688) 0.0018 5997 (46–19,516) n.s. 1709 (30–31,550) 0.0268
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2.5. Thalidomide Shows a Weak, Lenalidomide an Intermediate, and Pomalidomide a Strong Inhibitory Effect on
the TLR4/LPS-Induced Release of Soluble Mediators by Normal Monocytes
The supernatant levels of 14 soluble mediators were compared for monocyte cultures prepared
in medium with DMSO (i.e., control cultures) and cultures prepared in medium with DMSO and 5
µg/mL of either thalidomide, lenalidomide, or pomalidomide (Figure 5), Supplementary Figure S2,
Table 1). All three IMiDs modulated TLR4/LPS-induced soluble mediator release by normal monocytes,
but the effects differed among the drugs. First, thalidomide caused a significant reduction for only
three mediators (CCL2, IL10, MMP9) and a highly significant effect was only seen for MMP9. Second,
lenalidomide caused a significant reduction for five mediators, but a highly significant effect was only
seen for CCL2. Third, pomalidomide caused a significant reduction for seven mediators and the effect
was generally stronger (i.e., lower p-values) for pomalidomide than for the other two IMiDs (Table 1,
Supplementary Figure S2). A generally stronger effect (i.e., lower concentrations) by pomalidomide
was also observed when comparing the absolute levels for cultures with LPS + pomalidomide versus
LPS + thalidomide/lenalidomide (Supplementary Table S2).
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Figure 5. The effects of IMiDs on TLR4/LPS-stimulated cytokine release by normal monocytes; a
hierarchical clustering analysis of the overall IMiD effects. The analysis was based on the relative
mediator level, i.e., level in IMiD-containing LPS cult res lative to the level in the corresponding LPS
stimulated IMiD-free control. Bef re the clustering analysis ll relative respons s for each mediator
were normaliz d t the m ian relativ response for all three IMiDs, i.e., they were normalized to
the edian relative r spo s of all 45 IMID responses for each mediator (3 IMiDs, 15 individuals).
Thus, green color thus means a relatively strong inhibitory effect. It can be se n that even for mediators
showing highly significant effects of IMiDs there was a con iderable variation among individuals with
regard to the effects of IMiDs.
We also did a hierarchical clustering analysis including all the drugs and all the mediators
(Figure 5). This analysis was based o the relative mediator levels in drug-containing cultures,
i.e., levels in IMiD cultures relative to the level in the corresponding LPS control culture. Each of these
relative responses for a mediator was next normalized to the median relative response for all three
IMiDs, i.e., the median relative response of the 45 IMID responses for each soluble mediator (3 drugs
times 15 individuals). It can be seen that even for mediators showing highly significant overall effects
of IMiDs there was a considerable variation among individuals with regard to the effect.
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Furthermore, weaker responses were often seen for the lower cluster including six patients, and all
these patients showed relatively strong TLR4/LPS responses (see Supplementary Figure S3). Thus, the
effect of IMiDs in the presence of TLR4/LPS stimulation seemed to depend on the LPS responsiveness,
and the IMiD effects were stronger for patients with a relatively weak TLR4/LPS responsiveness.
2.6. Lenalidomide and Pomalidomide Reduce TLR4/LPS-Induced Mediator Release by Normal Monocytes Also
at Concentrations Corresponding to Their Therapeutic Serum Levels
Thalidomide was tested at a concentration corresponding to its therapeutic serum level
(i.e., 5 µg/mL) in the previous experiments, whereas lenalidomide and pomalidomide in vivo levels
are lower than this. We therefore tested the effect of lenalidomide 500 ng/mL and pomalidomide
100 ng/mL on the TLR4/LPS-induced mediator release for five healthy donors, and both these IMiDs
could inhibit soluble mediator release even when tested at the lower concentrations corresponding to
their serum levels (uncorrected p-value of 0.031, Wilcoxon test for paired samples).
2.7. Pomalidomide Inhibits Soluble Mediator Release also in the Presence of Bortezomib
The effect of the proteasomal inhibitor bortezomib was tested for five healthy blood donors (two
males and three females, median age 63 years with range 21–66 years) when monocytes were cultured
in medium alone or in the presence of LPS. Bortezomib had minor and divergent effects when testing
monocytes cultured in medium alone (data not shown), whereas it caused an inhibition of CCL1
and CXCL10 for all five individuals when tested in the presence of LPS (Figure 6). Furthermore,
we tested whether the inhibitory effects of lenalidomide and pomalidomide on TLR4/LPS-induced
release by normal monocytes was maintained in the presence of bortezomib. An inhibitory effect of
pomalidomide was observed for a limited number of mediators also in the presence of bortezomib,
whereas lenalidomide had generally weaker and divergent effect (Figure 6).
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Figure 6. The effects of TLR4/LPS, bortezomib, and IMiDs on the release of soluble mediators by 
normal monocytes; a summary of the overall results for five healthy blood donors. We compared the 
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a similar decrease (i.e., at least 25% reduction) in the soluble mediator level for all five individuals 
included in the comparisons are indicated in grey; a decrease for all five individuals corresponds to 
an uncorrected p-value of 0.031 when using the Wilcoxon test for paired samples. 
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3. Discussion
Normal monocytes seem important both in immunoregulation and possibly also for
carcinogenesis/leukemogegesis [1,17]. The aim of the present study was therefore to investigate
whether monocyte functions are altered by IMiDs, a class of pharmacological agents that have cereblon
as a common intracellular molecular target [2] and are considered for the treatment of various cancers,
especially hematological malignancies [1,27,28]. Our main conclusion based on the present study is
that IMiDs can alter both monocyte metabolism as well as cytokine release, and despite their common
molecular target these pharmacological effects differ among IMiDs.
Thalidomide and its derivatives lenalidomide and pomalidomide are used in the treatment of
multiple myeloma [29–34]. The antimyeloma effect is probably due to both direct and indirect effects
on the myeloma cells, including immunomodulation as well as anti-angiogenic, anti-inflammatory
and direct antiproliferative effects [31,32,35]. These drugs are often combined with steroids and/or
proteasome inhibitors [34] and can be used in frontline therapy [34]. The E3 ligase protein cereblon is a
well-characterized molecular target of IMIDs [36,37], but animal studies suggest that IMiDs also have
other intracellular targets [37]. The binding to cereblon modulates the stability of cereblon-interacting
molecules [36] and thereby promotes apoptosis by activating caspase-8 [38]. However, the clinical
evidence suggests that there are important pharmacological differences among IMiDs, and resistance
against one IMiD does not exclude a response to another IMiD [39]. In the present study we investigated
how IMiDs differ in their effects on normal monocytes.
TLR4 is expressed by human monocytes [11,12,40]. LPS is a TLR4 ligand that initiates the
activation of several downstream intracellular pathways in monocytes, including NFκB, extracellular
signal-regulated kinases (ERK) 1 and 2, c-Jun N-terminal kinase (JNK) and p38 pathways that
activate several transcription factors [11,12]. The signaling leads to metabolic modulation and a
well-characterized cytokine release response including chemokines, TNFα, IL8/CXCL8, and members
of the IL1 family [41]. Furthermore, TLR4 binds microbial molecules as well as several host-derived
ligands, e.g., molecules derived from degradation of extracellular matrix molecules (e.g., hyaluronic
acid, heparin sulphate), heat shock proteins, fibrinogen, lipoproteins, and amyloid [9,10]. Thus, TLR4 is
both a cellular sensor of the extracellular microenvironment and a regulator of cellular communication.
In this context we investigated the effects of IMiDs on monocyte metabolism and cytokine release in
the presence of TLR4 activation.
We used highly standardized in vitro models for our comparison of pharmacological effects. The
same medium was used in all studies. This medium was supplemented with inactivated fetal calf
serum, and the monocytes were thereby exposed to lipids during culture. Stimulation of TLR4 by
lipids or lipoproteins may at least partly explain why monocytes show spontaneous release of several
soluble mediators during culture, even in the absence of TLR4 stimulation [42].
Our monocyte populations had a purity exceeding 83%, and a major part of the contaminating
cells were small lymphocytes. Furthermore, we cultured the cell for only 24 h, whereas lymphocyte
activation will often require a longer incubation time for cytokine release, even during mitogenic
stimulation [43]. For these reasons we regard our cytokine responses to be monocyte responses.
Thalidomide (molecular weight 358), lenalidomide (359), and pomalidomide (372) were tested
at a concentration of 5.0 µg/mL, and due to these minor differences in molecular weight their molar
levels in the cultures should in our opinion be regarded as comparable. However, despite comparable
molar levels the IMiDs differed in their pharmacological effects; lenalidomide showed a stronger effect
on monocyte metabolism, whereas pomalidomide had the most significant effect on soluble mediator
release. This last difference in their effects on cytokine release is probably not caused by different
effects on monocyte viability; if so, one would expect all mediators to be affected and not only certain
mediators, as we observed.
The concentration of 5 µg/mL was chosen because this is the systemic level reached during
thalidomide treatment of myeloma patients [44]. However, the systemic levels of lenalidomide and
pomalidomide are usually lower, and for this reason we also tested lenalidomide and pomalidomide
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at levels corresponding to their systemic levels reached during myeloma treatment (i.e., 500 and
100 ng/mL, respectively) [45–47]. These experiments showed that both lenalidomide and pomalidomide
reduced monocyte release of soluble mediators also when tested at these lower concentrations.
Our studies showed that LPS as expected altered monocyte metabolism in the direction of
glycolysis [41]. IMiDs could further modulate the metabolism of normal monocytes in the presence
of TLR/LPS stimulation, and lenalidomide had the strongest effects, with a significant increase in the
OCR:ECAR ratio (i.e., increased importance of glycolysis) and an increased spare respiratory capacity.
These observations were only made in the presence of TLR4/LPS stimulation but not when cells were
cultured in medium alone, an observation demonstrating that the differences between IMiDs with
regard to metabolic modulation depend on the biological context. Finally, even though lenalidomide
seems to have the strongest effect on metabolism, pomalidomide had the strongest effect on the
extracellular release of soluble mediators. Thus, the IMiD effects on these phenotypic characteristics
are probably mediated at least partly through different molecular mechanisms.
There was a considerable variation among individuals with regard to the levels of the various
soluble mediators, and a possible explanation for this could be immunogenetic differences between
cell donors. Single nucleotide polymorphisms (SNPs) exist both for NKκB and TLR4 signaling [48–53],
and certain SNPs seem to be clinically relevant and are associated with differences in regulation of
monocyte activation. First, certain polymorphisms have been associated with cancer risk, and this is
possibly due to a genotypic influence on intracellular signaling [50,52]. Second, the risk and/or severity
of infections have also been associated with such genetic variants [49,53]. Finally, immunogenetic
characteristics may be important for the role of monocytes in the development of inflammations [51,53].
Both clinical and experimental studies suggest that differences in monocyte cytokine responsiveness
are important for the associations between immunogenetic differences and severity of infections [53],
but differences in TLR4 expression levels may also contribute [48]. In this context it is not surprising
that we detect a considerable variation among healthy individuals in the cytokine responsiveness of
normal monocytes to TLR4 ligation.
Proteasome inhibitors are also widely used in the treatment of multiple myeloma [27]. These
drugs inhibit the NFκB pathway, one of the pathways also activated by TLR4 [9], and may thereby be
able to reduce the release of NFκB-regulated soluble mediators [54]. Proteasome inhibitors and IMiDs
can be combined in myeloma treatment [27]. The proteasome inhibitor bortezomib had relatively weak
and divergent effects on the mediator release by normal monocytes and inhibited TLR4/LPS-induced
release only for a few mediators. However, bortezomib seemed to modulate the inhibitory effects of
IMiDs on the mediator release, and this was true especially for lenalidomide, whereas several effects of
pomalidomide were maintained also in the presence of bortezomib.
Infections are a major cause of morbidity and mortality in myeloma patients, and immunosuppressive
effects of IMiDs may contribute to the risk of infections [55]. Advanced myeloma is associated with
dysregulation of several immunocompetent cells [29], including monocytes [18,56–62]. The effects of IMiDs
on monocyte mediator release will influence communication between immunocompetent cells and possibly
contribute to the risk of infections. Myeloma patients receiving antimyeloma therapy seem to have a
quantitative monocyte defect [63] and our present results suggest that these patient also have a qualitative
effect, but in our opinion the myeloma-associated B-cell defect is probably most important for the increased
risk of infections [64].
Our present in vitro studies suggest that various IMiDs alter the metabolic regulation and the
immunomodulatory functions of normal monocytes, but for several reasons our results should be
interpreted with great care. First, additional clinical studies are needed to clarify whether these
effects are relevant in vivo. Second, normal monocytes consist of different subsets with different
immunoregulatory functions [17,65], and it is not known whether IMiDs have similar effects on
different monocyte subsets. Third, it is not known whether circulating normal monocytes derived
from cancer patients, especially allotransplant recipients [63,65], show similar pharmacological effects
compared with monocytes from healthy individuals, or whether the IMiD effects are similar for
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young/middle-aged/elderly patients. Finally, we have only investigated IMiDs in combination with the
proteasome inhibitor bortezomib; additional combinations used for treatment of multiple myeloma [27]
as well as for other hematological malignancies [28] also need to be investigated.
Based on our present experimental studies we conclude that IMiDs modulate metabolism and
communication of normal monocytes, and despite their common molecular target [2] these effects
differ among IMiDs. These pharmacological in vivo effects may be relevant for immunoregulatory
as well as cancer-supporting effects of normal monocytes [1,17], and future clinical studies should
therefore try to clarify whether these effects are also important in vivo.
4. Materials and Methods
4.1. Cell Donors
Normal monocytes were derived from healthy blood donors. In accordance with the approved
routines at the Blood Bank, Haukeland University Hospital peripheral venous blood samples were
donated after written informed consent. The project was approved by the Regional Ethics Committee
(REK VEST 2013/635, 2017/305).
4.2. Reagents
A stock solution of lipopolysaccharide (LPS) from Escherichia coli (#L2654-1MG; Merck KGaA,
Darmstadt, Germany) was dissolved in medium (1 mg/mL) and stored at −80 ◦C. LPS was used
at a concentration of 1 ng/mL based on titration experiments using monocytes in the Seahorse
assay. Bortezomib (#5043140001; Merck KGaA) was dissolved in medium and used at a final
concentration of 25 nM; this concentration can inhibit in vitro constitutive chemokine release by
myeloid cells [54]. Stock solutions of thalidomide 12 µg/mL (#14610), lenalidomide 16 µg/mL (#14643),
and pomalidomide 15 µg/mL (#19877; all from Cayman Chemicals, Ann Abor, MI) were prepared
in DMSO (D2650-5X5ML, Merck KGaA), aliquoted, and stored at −80 ◦C. DMSO reached a final
concentration of 0.55 mg/mL (corresponding to 0.055%) in the experiments. The molecular weights for
the IMiDs are thalidomide (C13H10N2O4) 258, lenalidomide (C13H13N3O3) 259, and pomalidomide
(C13H11N3O4) 273 (see Supplementary Figure S4). The IMiDs were used at a final concentration of
5 µg/mL; this concentration corresponds to the systemic levels reached in vivo during thalidomide
treatment of myeloma patients [44] (for molar concentrations, see Supplementary Figure S4).
4.3. Preparation of Enriched Normal Monocytes
Monocytes were isolated from buffy coats that were diluted 1:1 with phosphate-buffered saline
(PBS), and peripheral blood mononuclear cells (PBMC) were then isolated by density gradient
separation (Lymphoprep™, NycoMed, Oslo Norway; density 1.077 g/mL; centrifugation 800 G/30 min).
The PBMC were washed twice in PBS, resuspended in 5 mL RPMI 1640 medium (#R7509, Merck KGaA)
and overlaid 4 mL Percoll solution (P4937, Merck KGaA) [66]. After centrifugation (500 G, 30 min,
room temperature) monocytes were harvested, washed, resuspended in 30 mL PBS and counted by a
TC20™ Automated Cell Counter (BIO-RAD, Oslo, Norway).
The cells were thereafter centrifuged and resuspended (107 cells/40 µL in the recommended
buffer for the Pan Human Monocyte Isolation Kit (#130-096-537; MACS Miltenyi Biotec, Bergisch
Gladbach, Germany) and the separation procedure performed strictly according to the manufacturer’s
recommendations. Briefly, the LS column (#130-042-401, MACS Miltenyi Biotec), and the 30 µm
preseparation filter (#130-041-407, MACS Miltenyi Biotec) were prepared according to the instructions.
Cells were incubated with the FcR-block and Pan Monocyte Biotin–Antibody Cocktail for 5 min
at a concentration of 10 µl per 107 cells; an additional 40 µL of buffer per 107 cells was thereafter
added, followed by 20 µl Anti-Biotin MicroBeads per 107 cells. The cell suspension was thereafter
incubated for 10 min before buffer was added, the cells were centrifuged and resuspended in buffer at
a concentration of 108 cells/0.5 mL. Thereafter 0.5 mL of the cell suspension was added to the pre-filter
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and the suspension was run through the column and collected. The column was subsequently washed
with 3 mL buffer that was collected together with the monocytes. The collected cells were centrifuged
and reconstituted in 50 mL PBS before counting. Flow cytometric analysis of isolated cell populations
showed at least 83% monocytes (median 89.5%, range 83.4–95.3%); the majority of contaminating
cells being small lymphocytes. The monocytes included a median of 84% classical (range 76–90%),
5% (range 4.1–9.3%) intermediate, and 9% (range 4.8–18.4%) nonclassical monocytes. The monocytes
were centrifuged and resuspended in RPMI 1640 supplemented with 10% fetal calf serum (FCS) and
penicillin/streptomycin (1.25 x 106 cells/mL), and 200 µl were distributed to each culture well. After
30 min of preincubation at 37 ◦C the cells were used in the experiments.
4.4. Analysis of Monocyte Metabolism
In vitro culture of enriched monocytes. Monocytes were incubated for four hours in medium with
and without IMIDs/LPS before the medium was changed. Thereafter the cells were incubated for
one hour without CO2 before analysis by the Seahorse XF 96 cell analyzer. No significant difference
was detected for control cultures (with or without LPS) with and without DMSO. Pilot experiments
compared the effects of IMiDs after 2, 4, and 24 h of in vitro culture; the effects of IMiDs were strongest
after four hours and this incubation time was used for all experiments.
Extracellular flux assays. The XF Mito Stress Test Kit (#103,325-100 and #103,015-100; Agilent
Technologies, Inc., CA) was used strictly according to the manufacturer’s instructions. Briefly, assay
medium was prepared by supplementing XF Base Medium minimal DMED (#102,353-100; Agilent
Technologies) with glucose 10 mM (#103,577-100, Agilent Technologies), pyruvate 1 mM (S8,636-100 mL,
Merck KGaA), and glutamine at 2 mM (#103,575, Agilent Technologies); the pH was adjusted to 7.4
with NaOH. Cells were washed twice in assay medium before being resuspended in 180 µL medium
and incubated (humidified atmosphere, 37 ◦C, without CO2) for 60 min. The cartridges that had
been hydrated according to manufacturer instructions one day earlier, were prepared with the drugs
for injections, i.e., oligomycin 2 µM, carbonyl cyanide-p-trifluoromethox-yphenyl-hydrazon (FFCP,
a protonophore) 1 µM, and rotenone/antimycin A 0.5 µM (all solutions prepared in assay medium).
The extracellular flux assays were performed; subsequently the assay medium was discarded and the
plate stored at −80 ◦C for at least 24 h before the amount of protein was measured (see below). All
assays were prepared with 6–8 parallels.
The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were estimated
by a Seahorse XF 96 cell analyzer. The spare reservoir capacity and coupling efficiency was calculated
by XF Cell Mito Stress Test Excel Template. The definitions of the parameters used in the metabolic
analyses can be seen in Supplementary Figure S1 (upper part).
Estimation of total cell proteins. The Pierce™ BCA Protein Assay Kit (#23,225; Thermo Scientific™,
Waltham, MA, USA) was used for normalization of data and performed strictly accordingly to
manufacturer’s instructions. A total of 10 µl of standard samples was added to each well together with
200 µl of working reagent. After 30 s on a plate shaker and 30 min incubation 150 µl was transferred to
a new plate and read at 595 nm by a iMark™Microplate Absorbance Reader (Bio-Rad laboratories,
Oslo, Norway).
4.5. Analysis of TLR4/LPS Induced Cytokine Release
Enriched normal monocytes were cultured in RPMI 1640 medium (#R8758-1L; Merck KGaA)
supplemented with 10% inactivated fetal calf serum (#S181B-500; Biowest, Nuaillé, France) and
penicillin-streptomycin (#MS00AO100H; Biowest). Cultures were prepared in Agilent Seahorse XF95
cell culture microtiter (96-well) plates with each well containing 250,000 monocytes in 200 µl medium.
LPS 1 ng/mL was added together with the drugs, cultures were thereafter incubated (37 ◦C, humidified
atmosphere, 5% CO2) for 24 h before supernatants were harvested. The supernatants were stored
frozen at −20 ◦C until analyzed.
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Supernatant levels of soluble mediators were determined by Luminex high performance assays
(Biotechne, Abingdon, UK) and included CCL1, CCL7, CXCL10, IL-8, MMP-9, CCL2, CCL4, CXCL1,
IL-1β, and IL-10. ELISA assays (Biotechne) were used to determine levels of CCL3, IL1RA, IL6, and
TNF-α. All assays were performed strictly accordingly to the manufacturer’s instructions; the assays
were performed in duplicates and differences between duplicates were generally <10%.
4.6. Statistical Analysis
The Wilcoxon rank sum test and the Wilcoxon test for paired samples were used for statistical
analyses and p-values < 0.05 were regarded as statistically significant.
Supplementary Materials: The following are available online, Table S1: The spontaneous release of
soluble mediators, an overview; Table S2. The effects of thalidomide, lenalidomide, and pomalidomide on
TLR4/LPS-induced release of soluble mediators by normal monocytes derived from healthy individuals; a
comparison of the effects of the three pharmacological agents; Figure S1: Analysis of monocyte metabolism
using The XF Mito Stress Test assay and the Seahorse XF 96 cell analyzer; an overview of the Seahorse assay
(upper part) and the results from a representative experiment (lower part); Figure S2: The effects of TLR4/LPS
activation and IMiDs on the release of soluble mediators by normal monocytes; a summary of the results for
15 healthy blood donors presented in Table 1 in the article; and Figure S3: A hierarchical clustering analysis of
the TLR4/LPS-induced stimulation of soluble mediator release by normal monocytes. Figure S4: The chemical
structure of the three IMiDs investigated (thalidomide, lenalidomide, and pomalidomide), their molecular weights,
and the molar concentrations corresponding to 5 µg/mL.
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